BRIEF—Amphastar settles litigation over Lovenox copycats

Amphastar Pharmaceuticals has entered into an agreement which will see Momenta Pharmaceuticals and Novartis’ US-based generics arm Sandoz pay nearly $60 million to settle ongoing litigation.

While Sandoz and Momenta were the first to market with a generic version of Sanofi’s Lovenox (enoxaparin), Amphastar was able to launch its own generic, despite patent infringement claims.

Amphastar subsequently countersued with an antitrust suit against its partners. The agreement will result in the dismissal of all pending litigation between the parties.